ClinicalTrials.gov
ClinicalTrials.gov Menu

RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03633084
Recruitment Status : Recruiting
First Posted : August 16, 2018
Last Update Posted : October 19, 2018
Sponsor:
Information provided by (Responsible Party):
Ribomic USA Inc

Brief Summary:
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.

Condition or disease Intervention/treatment Phase
Age-related Macular Degeneration Drug: RBM-007 Injectable Solution Phase 1 Phase 2

Detailed Description:
Nine subjects in three dose cohorts (3 subjects each cohort) will receive a single i.vt. injection of RBM-007 in the study eye. Subjects will be followed through Day 56.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open label, non-controlled, sequential, dose-escalating study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Actual Study Start Date : August 29, 2018
Estimated Primary Completion Date : August 15, 2019
Estimated Study Completion Date : August 15, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: RBM-007 Injectable Solution - Dose 1
No additional information.
Drug: RBM-007 Injectable Solution
(No additional description)

Experimental: RBM-007 Injectable Solution - Dose 2
No additional information.
Drug: RBM-007 Injectable Solution
(No additional description)

Experimental: RBM-007 Injectable Solution - Dose 3
No additional information.
Drug: RBM-007 Injectable Solution
(No additional description)




Primary Outcome Measures :
  1. Ocular safety as assessed using biomicroscopy to investigate ocular tolerability [ Time Frame: Day 56 ]
    Biomicroscopy (as conducted by ophthalmologist)

  2. Ocular safety as assessed using ophthalmoscopy to investigate ocular tolerability [ Time Frame: Day 56 ]
    Ophthalmoscopy (as conducted by ophthalmologist)


Secondary Outcome Measures :
  1. Ocular tolerability as assessed by number and nature of adverse events [ Time Frame: Day 56 ]
    Adverse events

  2. Retinal fluid [ Time Frame: Day 56 ]
    As measured by Optical coherence tomography



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female 55 years of age or older on the date of signing the informed consent form and able and willing to comply with all treatment and follow-up study procedures.
  2. At Screening Visit, subjects must meet all the following inclusion criteria:
  3. Must have had prior treatment in the study eye with any intravitreal vasoactive endothelial growth factor (VEGF) medication (at least 3 anti-VEGF) treatments within the prior 2-6 months), throughout which clinical examination and SD-OCT imaging has shown recurrent or persistent exudative activity, as shown by the presence of intraretinal or subretinal fluid, and/or subretinal exudation or hemorrhage.
  4. Best corrected visual acuity of 65 to 20 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters (20/50 to 20/400) in the study eye.
  5. Presence of significant subretinal fluid and/or cystoid macular edema secondary to exudative age-related macular degeneration as assessed by optical coherence tomography in the study eye, with a minimum of 300 µm within the central subfield.
  6. Total lesion size of ≤9 disc areas, lesion containing ≤50% hemorrhage and ≤50% subretinal fibrosis and ≤50% retinal pigment epithelial atrophy in the study eye.
  7. Reasonably clear media and reasonable fixation ability in the study eye to allow for good quality tomography and fundus photography.

    At Baseline Visit (Day 0), subjects must meet all the following inclusion criteria:

  8. Best Corrected Visual Acuity (BCVA) of 65 to 20 ETDRS letters (20/50 to 20/400) in the study eye.
  9. Presence of significant subretinal and/or intraretinal fluid secondary to exudative age-related macular degeneration as assessed by SD-OCT in the study eye, with a minimum of 300 µm within the central subfield.
  10. Total lesion size of ≤9 disc areas, containing ≤ 50% hemorrhage and ≤ 50% fibrosis and ≤ 50% retinal pigment epithelial atrophy in the study eye.

Exclusion Criteria:

Ocular exclusion criteria:

  1. BCVA better than 65 ETDRS letters (20/50) in the study eye.
  2. BCVA worse than 20 ETDRS letters (20/400) in study eye.
  3. Fellow eye BCVA worse than 35 ETDRS letters (20/200).

    Use of any of the following treatments to the study eye:

  4. Intravitreal anti-VEGF injection (ranibizumab, aflibercept or bevacizumab) in the study eye within the past 4 weeks or less prior to Baseline Visit and RBM-007 injection.
  5. Intravitreal or periocular corticosteroid, within 3 months prior to Baseline Visit (Day 0) and throughout the study;
  6. Fluocinolone acetonide intravitreal implant, within 12 months prior to Baseline Visit (Day 0) and throughout the study;
  7. Visudyne® (verteporfin) photodynamic therapy, within 3 months prior to Baseline Visit (Day 0) and throughout the study.
  8. Uncontrolled or advanced glaucoma, defined by an intraocular pressure (IOP) of >21 mmHg or cup/disc ratio > 0.8 while on medical therapy, or chronic ocular hypotony (<6 mmHg) in the study eye.
  9. Evidence of ocular disease other than exudative AMD in the study eye that may confound the outcome of the study (e.g., active diabetic retinopathy, posterior uveitis, adult vitelliform dystrophy, moderate/severe myopic degeneration).
  10. History of vitrectomy surgery in the study eye.
  11. Anticipated need for any ocular surgery involving the study eye during the course of the study.
  12. Nd:YAG laser capsulotomy within 28 days prior to Baseline Visit (Day 0) in the study eye.
  13. Intraocular surgery, including lens removal or ophthalmologic laser procedure, within 90 days prior to Baseline Visit (Day 0) in the study eye.
  14. Ocular or periocular infection in either eye.
  15. Pupillary dilation inadequate for good quality fundus photography in the study eye.
  16. Media opacity that would limit clinical visualization, fundus photography, fluorescein angiography, or SD-OCT evaluation in the study eye.
  17. History of herpetic ophthalmic infection in the study eye or adnexa.
  18. Presence of known toxoplasmosis or toxoplasmosis scar in either eye.
  19. Presence or history of any form of ocular malignancy including choroidal melanoma in the study eye.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03633084


Contacts
Contact: Yusuf Ali, PhD (707) 287 4313 yusuf.ali@ribomic.com

Locations
United States, California
Stanford University Recruiting
Stanford, California, United States, 94303
Contact: Diana Do, M.D.    650-724-7752    dianado@stanford.edu   
Sponsors and Collaborators
Ribomic USA Inc
Investigators
Study Director: Yusuf Ali, Ph.D. Ribomic USA Inc

Responsible Party: Ribomic USA Inc
ClinicalTrials.gov Identifier: NCT03633084     History of Changes
Other Study ID Numbers: RBM-007-001
First Posted: August 16, 2018    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pharmaceutical Solutions